ES2093765T3 - Derivados de 4-aril tiazoles o imidazoles. - Google Patents

Derivados de 4-aril tiazoles o imidazoles.

Info

Publication number
ES2093765T3
ES2093765T3 ES92200825T ES92200825T ES2093765T3 ES 2093765 T3 ES2093765 T3 ES 2093765T3 ES 92200825 T ES92200825 T ES 92200825T ES 92200825 T ES92200825 T ES 92200825T ES 2093765 T3 ES2093765 T3 ES 2093765T3
Authority
ES
Spain
Prior art keywords
derivatives
aryl
hydrogen
lower alkyl
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92200825T
Other languages
English (en)
Inventor
John Henry Pick
Robert Thomas Logan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2093765T3 publication Critical patent/ES2093765T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Polyurethanes Or Polyureas (AREA)

Abstract

DERIVADOS DE 4-ARILO-TIAZOL O IMIDAZOL. LA INVENCION TRATA DE UN DERIVADO DE 4-ARILO-TIAZOL O IMIDAZOL CON LA FORMULA DONDE X ES O O NOH, Y ES S O NR3, AR ES UN GRUPO ELEGIDO ENTRE FENIL, NAFTIL, TETRAHIDRONAFTIL, Y BIFENILO, R ES DE UNO HASTA CUATRO SUPLENTES ESCOGIDOS INDEPENDIENTEMENTE ENTRE HIDROGENO, HIDROXI, ALQUILO INFERIOR, ALCOXI INFERIOR, TIOALQUILO INFERIOR, CICLOALQUINO, HALOGENO, CF3, NO2, Y O TICOS SATURADOS CON 2-6 ATOMOS DE CARBON, Y R1 Y R2 SON INDEPENDIENTEMENTE HIDROGENO O ALQUILO INFERIOR, O FORMAN, EN CONJUNTO CON EL ATOMO DE NITROGENO EL CUAL ESTA ENLAZADO, UN ANILLO HETEROCICLICO, Y R3 ES HIDROGENO O ALQUILO INFERIOR; O UNA SAL DE LO MISMO ACEPTABLE EN CUANTO A LA FARMACEUTICA, CON LA CONDICION DE QUE SE EXCLUYE 4 OXAMIDA. LOS COMPUESTOS SEGUN LA INVENCION AUMENTAN LA SENSIBILIDAD DE LAS MIOFIBRILLAS CARDIACAS AL CALCIO Y POSEEN ACTIVIDAD DE INHIBICION DE FOSFODIESTERASA Y ACTIVIDAD BRONCODILATOR, Y SON UTILES EN EL TRATAMIENTO DE PACIENTES QUIENES SUFREN INSUFICIENCIA CARDIACA Y ASMA.
ES92200825T 1991-03-25 1992-03-23 Derivados de 4-aril tiazoles o imidazoles. Expired - Lifetime ES2093765T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91302573 1991-03-25

Publications (1)

Publication Number Publication Date
ES2093765T3 true ES2093765T3 (es) 1997-01-01

Family

ID=8208225

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92200825T Expired - Lifetime ES2093765T3 (es) 1991-03-25 1992-03-23 Derivados de 4-aril tiazoles o imidazoles.

Country Status (17)

Country Link
US (2) US5254575A (es)
EP (1) EP0506194B1 (es)
JP (1) JPH0597816A (es)
KR (1) KR920018037A (es)
AT (1) ATE141597T1 (es)
AU (1) AU648394B2 (es)
CA (1) CA2063172A1 (es)
DE (1) DE69212870T2 (es)
DK (1) DK0506194T3 (es)
ES (1) ES2093765T3 (es)
FI (1) FI921262L (es)
GR (1) GR3021260T3 (es)
IE (1) IE73235B1 (es)
MX (1) MX9203810A (es)
NO (1) NO301929B1 (es)
NZ (1) NZ242095A (es)
ZA (1) ZA921781B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
WO1998019672A1 (en) * 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
AU6030098A (en) * 1997-01-16 1998-08-07 Neorx Corporation Phalloidin derivatives and analogs to treat congestive heart failure
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
CA2522476A1 (en) * 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
TWI336697B (en) * 2003-09-19 2011-02-01 Solvay Pharm Bv Thiazole derivatives as cannabinoid receptor modulators
TW200732314A (en) * 2005-10-26 2007-09-01 Smithkline Beecham Corp Substituted thiazoles and their use
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP4706758A3 (en) 2019-05-21 2026-05-06 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU168036B (es) * 1973-11-09 1976-02-28
FR2261756A1 (en) * 1974-02-27 1975-09-19 Roussel Uclaf 2-Thiazole-N-(Piperazino or piperidino) alkyl carboxamides - as hypotensive and anti-hypertensive agents of low toxicity
EP0199968B1 (en) * 1985-03-27 1990-02-28 Zenyaku Kogyo Kabushiki Kaisha Thiazole derivatives
JPH02262562A (ja) * 1988-10-20 1990-10-25 Ishihara Sangyo Kaisha Ltd イミダゾール系化合物

Also Published As

Publication number Publication date
KR920018037A (ko) 1992-10-21
EP0506194A1 (en) 1992-09-30
US5254575A (en) 1993-10-19
FI921262A7 (fi) 1992-09-26
JPH0597816A (ja) 1993-04-20
MX9203810A (es) 1992-07-31
AU648394B2 (en) 1994-04-21
DK0506194T3 (da) 1996-12-23
NO921156D0 (no) 1992-03-24
DE69212870T2 (de) 1997-01-16
EP0506194B1 (en) 1996-08-21
AU1291592A (en) 1992-10-01
NO921156L (no) 1992-09-28
FI921262L (fi) 1992-09-26
US5462959A (en) 1995-10-31
FI921262A0 (fi) 1992-03-24
IE920734A1 (en) 1992-10-07
CA2063172A1 (en) 1992-09-26
NZ242095A (en) 1994-04-27
DE69212870D1 (de) 1996-09-26
ATE141597T1 (de) 1996-09-15
GR3021260T3 (en) 1997-01-31
ZA921781B (en) 1992-11-25
NO301929B1 (no) 1997-12-29
IE73235B1 (en) 1997-05-21

Similar Documents

Publication Publication Date Title
ES2093765T3 (es) Derivados de 4-aril tiazoles o imidazoles.
ATE218549T1 (de) Verbindungen als pde iv und tnf inhibitoren
DE69233113D1 (de) Kondensierte heterocyclische Verbindungen, ihre Herstellung und Verwendung
DE69109631D1 (de) 2-Substituierte Adenosinderivate und pharmazeutische Zusammensetzungen zur Verwendung gegen Infektionskrankheiten.
ATE73815T1 (de) Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten.
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
DE3781080D1 (de) 2-substituierte-e-kondensierte(1,2,4)triazolo-(1,5-c)pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
EA200400936A1 (ru) ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-ПИРИДИНИЛ- И 2-ПИРИМИДИНИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА
AR016210A1 (es) Derivador de tienilazolilalcoxietanamina y sus sales fisiologicamente aceptables, procedimientos para obtener dichos derivados, sus enantiomeros puros ydichas sales, las composiciones farmaceuticas que los contienen, el empleo de dichos derivados para la preparacion de medicamentos, los compuestosin
ES2136291T3 (es) Derivados de pirimidina.
ES2073258T3 (es) Nuevos derivados de la urea, su preparacion y su aplicacion en terapeutica.
DE69229637D1 (de) Oxazolidone Derivative als Monoamine-Oxidaseinhibitoren
DK0780125T3 (da) Anvendelse af hydantoinderivater til fremstilling af et lægemiddel til behandling af sygdomme associeret med tilstedeværelse af aktivt oxygen og frie radikaler
ES2091489T3 (es) Derivados de imidazol y composiciones farmaceuticas que los contienen.
DE59002721D1 (de) Verfahren zur Behandlung der cardialen sowie der vasculären Hypertrophie und Hyperplasie.
KR890014112A (ko) 퀴놀리진 및 퀴놀리지논 유도체의 심장 부정맥 치료용 의약품 제조에 있어서의 용도
NO873189L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrido (2,3-b)(1,4)benzodiazepin-6-on-derivater.
ATE71092T1 (de) Hydroxybutenolid-derivate, ihre herstellung und ihre verwendung.
DE69324910D1 (de) Triazolopyrimidinderivate als angiotensin-ii rezeptor antagonisten
FR2618435B1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
ATE18761T1 (de) Carbamoyloxybenzhydrol-derivate, ihre herstellung und ihre pharmazeutische zusammensetzungen.
DK360388D0 (da) Laegemiddel til behandling af hjerteinsufficiens
ATE81466T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
DE3884878D1 (de) Uricosuretische Zusammensetzung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 506194

Country of ref document: ES